Clinical Trials
- Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) In HER2 Positive, Stage IIV Endometrial Serous Carcinoma or Carcinosarcoma
- Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) In HER2 Positive, Stage IIV Endometrial Serous Carcinoma or Carcinosarcoma
- Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) In HER2 Positive, Stage IIV Endometrial Serous Carcinoma or Carcinosarcoma
- Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) In HER2 Positive, Stage IIV Endometrial Serous Carcinoma or Carcinosarcoma
- Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) In HER2 Positive, Stage IIV Endometrial Serous Carcinoma or Carcinosarcoma
- Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) In HER2 Positive, Stage IIV Endometrial Serous Carcinoma or Carcinosarcoma
- Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) In HER2 Positive, Stage IIV Endometrial Serous Carcinoma or Carcinosarcoma
- Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) In HER2 Positive, Stage IIV Endometrial Serous Carcinoma or Carcinosarcoma
- Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) In HER2 Positive, Stage IIV Endometrial Serous Carcinoma or Carcinosarcoma
- Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) In HER2 Positive, Stage IIV Endometrial Serous Carcinoma or Carcinosarcoma
- Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) In HER2 Positive, Stage IIV Endometrial Serous Carcinoma or Carcinosarcoma
- Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-ZZXF (Phesgo) In HER2 Positive, Stage IIV Endometrial Serous Carcinoma or Carcinosarcoma
- Phase I, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors